Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study
Cameron J. Turtle(The University of Sydney), Nina Shah(The University of Texas MD Anderson Cancer Center), Andrew J. Cowan(University of Washington Medical Center), Alexandre V. Hirayama(University of Washington), Hayder Saeed(University of Kentucky), Murali Janakiram(University of Minnesota), Mario Q. Marcondes(Nektar Therapeutics (United States)), Krina K. Patel(University of Vermont), Kazuharu Kai(Nektar Therapeutics (United States)), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), Kaichun Wu(Xijing Hospital), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Julio C. Chávez(Moffitt Cancer Center), Xiaoli Wang(First Affiliated Hospital of Jiangxi Medical College), Zachary Lee(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Neha Dixit(Nektar Therapeutics (United States)), Delaney R. Kirchmeier(Fred Hutch Cancer Center)
Cited by 6
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k